Effect of an Oral Adsorbent, AST-120, on Dialysis Initiation and Survival in Patients with Chronic Kidney Disease. (12th January 2012)

• Record Type: Journal Article
• Authors: Hatakeyama, Shingo; Yamamoto, Hayato; Okamoto, Akiko; Imanishi, Kengo; Tokui, Noriko; Okamoto, Teppei; Suzuki, Yuichiro; Sugiyama, Naoaki; Imai, Atsushi; Kudo, Shigemasa; Yoneyama, Takahiro; Hashimoto, Yasuhiro; Koie, Takuya; Kaminura, Noritaka; Saitoh, Hisao; Funyu, Tomihisa; Ohyama, Chikara
• Other Names: Reiser Jochen Academic Editor.
• Is Part Of: International journal of nephrology. Volume 2012(2012)
• Publication Date: 2012-01-12
• Subjects: Nephrology -- Periodicals; Nephrology; Kidney Diseases; Nephrology; Periodicals; Periodicals; Fulltext; Internet Resources; Electronic journals; 616.61
• DOI: 10.1155/2012/376128
• Languages: English
• ISSNs: 2090-214X

Abstract

Abstract : The oral adsorbent AST-120 has the potential to delay dialysis initiation and improve survival of patients on dialysis. We evaluated the effect of AST-120 on dialysis initiation and its potential to improve survival in patients with chronic kidney disease. The present retrospective pair-matched study included 560 patients, grouped according to whether or not they received AST-120 before dialysis (AST-120 and non-AST-120 groups). The cumulative dialysis initiation free rate and survival rate were compared by the Kaplan-Meier method. Multivariate analysis was used to determine the impact of AST-120 on dialysis initiation. Our results showed significant differences in the 12- and 24-month dialysis initiation free rate (P < 0.001 ), although no significant difference was observed in the survival rate between the two groups. In conclusion, AST-120 delays dialysis initiation in chronic kidney disease (CKD) patients but has no effect on survival. AST-120 is an effective therapy for delaying the progression of CKD.